Bioventix Plc Interim Dividend Confirmation

 
TIDMBVXP 
 
Bioventix plc 
 
                        ("Bioventix" or the "Company") 
 
                         Interim dividend confirmation 
 
Bioventix plc (BVXP) ("Bioventix" or "the Company"), a UK company specialising 
in the development and commercial supply of high-affinity monoclonal antibodies 
for applications in clinical diagnostics, announces that the Board has 
confirmed a cash interim dividend of 52p per ordinary share, which will be paid 
on 22 April 2022. 
 
The dividend timetable dates are below: 
 
Ex-dividend date:               7 April 2022 
 
Record date:                    8 April 2022 
 
Payment date:                   22 April 2022 
 
For further information please contact: 
 
Bioventix plc 
Peter Harrison 
Chief Executive Officer  Tel: [phone] 
 
finnCap Ltd 
Geoff Nash/Simon Hicks 
Alice Lane 
Corporate Finance 
ECM      Tel: [phone] 
 
About Bioventix plc: 
 
Bioventix (www.bioventix.com) specialises in the development and commercial 
supply of high-affinity monoclonal antibodies with a primary focus on their 
application in clinical diagnostics, such as in automated immunoassays used in 
blood testing. The antibodies created at Bioventix are generated in sheep and 
are of particular benefit where the target is present at low concentration and 
where conventional monoclonal or polyclonal antibodies have failed to produce a 
suitable reagent. Bioventix currently offers a portfolio of antibodies to 
customers for both commercial use and R&D purposes, for the diagnosis or 
monitoring of a broad range of conditions, including heart disease, cancer, 
fertility, thyroid function and drug abuse. Bioventix currently supplies 
antibody products and services to the majority of multinational clinical 
diagnostics companies. Bioventix is based in Farnham, UK and its shares are 
traded on AIM under the symbol BVXP. 
 
 
 
END 
 
 

(END) Dow Jones Newswires

March 29, 2022 02:00 ET (06:00 GMT)